Overview
Elevian is a clinical-stage biopharmaceutical company developing recombinant protein therapeutics designed to restore regenerative capacity and address age-related diseases. The company's lead program, rGDF11, targets stroke recovery and has demonstrated efficacy in preclinical models of cardiovascular, neurological, metabolic, and inflammatory conditions. Elevian's approach leverages circulating growth factors discovered at Harvard to promote neovascularization, neurogenesis, and tissue repair. The company aims to transform treatment paradigms for acute neurological injuries and chronic age-related pathologies by targeting fundamental mechanisms of aging and regenerative decline.